Posters
Intrastromal corneal ring segment implantation in young patients under 20 years old with keratoconus: clinical results and disease progression after a 2 year follow-up
Poster Details
First Author: R.Carneiro de Freitas PORTUGAL
Co Author(s): T. Monteiro F. Faria-Correia N. Franqueira F. Vaz
Abstract Details
Purpose:
To evaluate visual, refractive and topographic results after Ferrara-type intrastromal corneal ring segments (ICRS) implantation for keratoconus treatment in patients under 20 years of age.
Setting:
Ophthalmology department of Hospital de Braga
Methods:
A retrospective study was conducted (between 2012 and February 2017 at the Ophthalmology department of Hospital de Braga) in patients under 20 years of age with keratoconus submitted to ICRS implantation with manual mechanical technique. The following parameters were analyzed: uncorrected distance visual acuity (UDVA), best corrected visual acuity (BCVA), refractive sphere and cylinder, keratometry (k), corneal aberrometry and central corneal thickness (CCT). Patients were evaluated at preop, 6, 12 and 24 months. Corneal topography was performed using Oculus Pentacam (OCULUS Optikgerate GmbH�Â�®, Wetzlar, Germany).
Results:
A total of 42 eyes of 35 patients with a mean age of 17,24 years(�Â�±2,37) were analyzed. Mean UDVA improved from 0,18�Â�±0,15 to 0,42�Â�±0,16 at 24 months (p<0,05). CDVA improved from 0,48�Â�±0,21 to 0,66�Â�±0,14 (p<0,05) at 24 months follow-up. Mean sphere and cylinder improved from -2,14�Â�±3,63D to -0,29�Â�±0,59D (p<0,05) and from -3,21�Â�±2,08D to -1,32�Â�± 1,23D (p<0,005) at 24 months, respectively. At 6 months, mean K1, K2, Kmax, topographic astigmatism and coma values decreased (p<0,05). Topographic parameters and corneal pachimety were stable between 6, 12 and 24 months, with no significant differences during follow-up after the immediate postoperative result.
Conclusions:
The implantation of ICRS showed good visual, refractive and topographic results in patients under 20 years of age while maintaining stability along a 24 months follow-up period, showing its potential to halt the disease progression even in a young patient population.
Financial Disclosure:
NONE
